Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease

Journal of Neurology

Volumn 261, Issue 3, 2014, Pages 561-569

  Cáceres Redondo, María T ^a   Carrillo, Fátima ^a   Lama, María J ^a   Huertas Fernández, Ismael ^a   Vargas González, Laura ^a   Carballo, Manuel ^a   Mir, Pablo ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Advanced Parkinson's disease; LCIG; Long term

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; FOLIC ACID; IMMUNOGLOBULIN; NEUROLEPTIC AGENT; PRAMIPEXOLE; ANTIPARKINSON AGENT; CARBIDOPA; DRUG COMBINATION; GEL; LEVODOPA;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG INFUSION; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; FOLLOW UP; GASTROSTOMY; GRANULOMA; HUMAN; INFUSION SYSTEM; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MIGRATION; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHLEGMON; PNEUMOPERITONEUM; POLYNEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SURGICAL INFECTION; COGNITION DISORDERS; COMPLICATION; DRUG COMBINATION; GEL; INFUSION; MILD COGNITIVE IMPAIRMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; COGNITION DISORDERS; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTROSTOMY; GELS; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896491315     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7235-1     Document Type: Article

References (25)

1. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123:2297-2305
2. Obeso JA, Rodriguez-Oroz M, Marín C et al (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 13:17-30
3. Castrioto A, Lozano AM (2011) Ten year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 68:1550-1556
4. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease- long-term experience. Acta Neurol Scand 104:343-348
5. Nyholm D, Nilsson Remahl AI, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson's disease. Neurology 25:216-223
6. Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
7. Crum RM, Anthony JC, Bassett SS et al (1993) Population based norms for the Mini-Mental State Examination by age and education level. JAMA 269:2386-2391
8. Caviness JN, Driver-Dunckley E, Connor DJ et al (2007) Defining mild cognitive impairment in Parkinson's disease. Mov Disord 15:1272-1277
9. Zibetti M, Merola A, Ricchi V et al (2013) Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 260:101-114
10. Emre M, Aarsland D, Brown R et al (2007) Clinica diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 15:1689-1707
11. Santos-García D, Sanjurjo LF, Macías M et al (2012) Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand 125:187-191
12. Nilsson D, Hansson LE, Johansson K et al (1998) Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 97:175-183
13. Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25:2649-2653
14. Antonini A, Isaias IU, Canesi M et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149
15. Puente V, De Fabregues O, Oliveras C et al (2010) Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 16:218-221
16. Levy G, Schupf N, Tang MX et al (2002) Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51:722-729
17. Foltynie T, Brayne C, Barker RA (2002) The heterogeneity of idiopathic Parkinson's disease. J Neurol 249:138-145
18. Guimarães J, Moura E, Vieira-Coelho MA et al (2012) Weight variation before and after surgery in Parkinson's disease: a noradrenergic modulation? Mov Disord 27:1078-1082
19. Toth C, Brown MS, Furtado S et al (2008) Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 23:1850-1859
20. Santos-García D, de la Fuente-Fernández R, Valldeoriola F et al (2012) Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 259:1668-1672
21. Müller T, van Laar T, Cornblath DR et al (2013) Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19:501-507
22. Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28-36
23. Müller T (2008) Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 8:957-967
24. Müller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 24:1339-1343
25. Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord 28:1931-1937